-- Days : -- HRS : -- MIN : -- SEC

Register Now →

Spotlight -

AMCP Nexus 2026|

State of the Industry survey: Share your 2027 outlook|

Bronchiectasis

CME Content

Immunotherapy Across the SCLC Continuum: Optimizing Treatment Pathways From Limited-Stage Through Relapsed Disease | Florida Regional Program

Immunotherapy Across the SCLC Continuum: Optimizing Treatment Pathways From Limited-Stage Through Relapsed Disease | Florida Regional Program

Frantz Francisque, MD; Jacob Sands, MD

Immunotherapy Across the SCLC Continuum: Optimizing Treatment Pathways From Limited-Stage Through Relapsed Disease | Michigan Regional Program

Immunotherapy Across the SCLC Continuum: Optimizing Treatment Pathways From Limited-Stage Through Relapsed Disease | Michigan Regional Program

Jacob Sands, MD; Shiven B. Patel, MD, MBA, FACP

Personalized Approaches in NSCLC: Early Detection, Molecular Testing, and Targeted Therapies

Personalized Approaches in NSCLC: Early Detection, Molecular Testing, and Targeted Therapies

Charu Aggarwal, MD, MPH, FASCO; Zofia Piotrowska, MD, MHS

Immunotherapy Across the SCLC Continuum: Optimizing Treatment Pathways From Limited-Stage Through Relapsed Disease | Alabama Regional Program

Immunotherapy Across the SCLC Continuum: Optimizing Treatment Pathways From Limited-Stage Through Relapsed Disease | Alabama Regional Program

Benjamin Scheier, MD; Christine L. Hann, MD, PhD

Immunotherapy Across the SCLC Continuum: Optimizing Treatment Pathways From Limited-Stage Through Relapsed Disease | Tennessee Oncology Practice Society

Immunotherapy Across the SCLC Continuum: Optimizing Treatment Pathways From Limited-Stage Through Relapsed Disease | Tennessee Oncology Practice Society

Jack W. Erter III, MD, MMHC; Anne Chiang, MD, PhD

Immunotherapy Across the SCLC Continuum: Optimizing Treatment Pathways From Limited-Stage Through Relapsed Disease | Illinois Regional Program

Immunotherapy Across the SCLC Continuum: Optimizing Treatment Pathways From Limited-Stage Through Relapsed Disease | Illinois Regional Program

Benjamin Scheier, MD; Christine L. Hann, MD, PhD

Immunotherapy Across the SCLC Continuum: Optimizing Treatment Pathways From Limited-Stage Through Relapsed Disease | Indiana Oncology Society

Immunotherapy Across the SCLC Continuum: Optimizing Treatment Pathways From Limited-Stage Through Relapsed Disease | Indiana Oncology Society

Benjamin Scheier, MD; Christine L. Hann, MD, PhD

Immunotherapy Across the SCLC Continuum: Optimizing Treatment Pathways from Limited-Stage Through Relapsed Disease

Immunotherapy Across the SCLC Continuum: Optimizing Treatment Pathways from Limited-Stage Through Relapsed Disease

Webinar Series

South Carolina Oncology Society

South Carolina Oncology Society

2 Sessions are Available!

Arizona Clinical Oncology Society

Arizona Clinical Oncology Society

1 Session is Available!

Hot Seat: Converging Lines in the Management of RAS-Altered Cancers

Hot Seat: Converging Lines in the Management of RAS-Altered Cancers

Shubham Pant, MD, MBBS; Alison Schram, MD; Helena Yu, MD

Show Me the Data™: Incorporating the Latest Advances in Immunotherapy and EGFR-Targeted Treatments for Resectable, Early-Stage NSCLC

Show Me the Data™: Incorporating the Latest Advances in Immunotherapy and EGFR-Targeted Treatments for Resectable, Early-Stage NSCLC

Mara Antonoff, MD, FACS; Laura Alder, MD; Stephanie Worrell, MD, FACS

Tumor Board: Translating HER2 and TROP2 Innovations to Transform NSCLC Care

Tumor Board: Translating HER2 and TROP2 Innovations to Transform NSCLC Care

Jacob Sands, MD; Marina Chiara Garassino, MD; Eric K. Singhi, MD

Live Tumor Board: From Trial to Practice–Integrating the Latest Evidence Into the Treatment of EGFR-Mutated NSCLC

Live Tumor Board: From Trial to Practice–Integrating the Latest Evidence Into the Treatment of EGFR-Mutated NSCLC

Jonathan Riess, MD, MS; Fawzi Abu Rous, MD; Julia Rotow, MD

Burst CME Expert Illustrations & Commentaries™: Breaking Down DLL3-Targeting Immune Cell Effector Agents in SCLC

Burst CME Expert Illustrations & Commentaries™: Breaking Down DLL3-Targeting Immune Cell Effector Agents in SCLC

Jacob Sands, MD; Anne Chiang, MD, PhD

Cases and Conversations™: Next-Generation Pathology Advances and Considerations for Precision Care in Non–Small Cell Lung Cancer

Cases and Conversations™: Next-Generation Pathology Advances and Considerations for Precision Care in Non–Small Cell Lung Cancer

Sanja Dacic, MD, PhD; Soo-Ryum (Stewart) Yang, MD; Isabel Preeshagul, DO, MBS

Show Me the Data™: Post-TKI Sequencing in EGFR-Mutated NSCLC—Optimizing Current Strategies and Preparing for New Treatment Modalities

Show Me the Data™: Post-TKI Sequencing in EGFR-Mutated NSCLC—Optimizing Current Strategies and Preparing for New Treatment Modalities

Christine M. Lovly, MD, PhD, FASCO; Xiuning Le, MD, PhD; Hossein Borghaei, DO, MS; Lyudmila Bazhenova, MD

Please check back later for more content.

Trending on Managed Healthcare Executive

CVS Health is splitting in two, according to news reports

Jeremy Gaskill on moving from Humana to Geisinger Health Plan

South Dakota voters reject Medicaid expansion trigger amendment

On the advantages of health system-owned health plan, what Medicaid cuts might mean and the future of U.S. health insurance: A conversation with Geisinger's Jeremy Gaskill

Christine Johnston on why Medicaid leads in biosimilar adoption